Literature DB >> 17876545

Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation.

Raffaele Pezzilli1, Alessandra Barassi, Antonio M Morselli-Labate, Lorenzo Fantini, Paola Tomassetti, Davide Campana, Riccardo Casadei, Sergio Finazzi, Gianvico Melzi d'Eril, Roberto Corinaldesi.   

Abstract

BACKGROUND: Fecal calprotectin determination has been demonstrated to be useful in diagnosing various inflammatory diseases of the gastrointestinal tract; however, data available for patients with pancreatic diseases are scarce. Our aim was to assess fecal calprotectin in order to evaluate the presence of intestinal inflammation in patients with pancreatic disease.
METHODS: Eligible patients with suspected pancreatic illness were enrolled, and in all of them fecal calprotectin and elastase-1, as well as serum amylase and lipase activities, were assayed using commercially available kits.
RESULTS: A total of 90 subjects (47 men, 43 women, mean age 58.6 +/- 14.9 years) were enrolled: 20 (22.2%) had chronic pancreatitis; 15 (16.7%) had pancreatic cancer; six (6.7%) had chronic nonpathological pancreatic hyperenzymemia; 16 (17.8%) had nonpancreatic diseases; and 23 (25.6%) had no detectable diseases. Diarrhea was present in 19 patients (21.1%). In univariate analyses, the presence of diarrhea and low fecal elastase-1 concentrations were significantly associated (P = 0.019 and P = 0.002, respectively) with abnormally high fecal calprotectin concentration, and the multivariate analysis demonstrated that low fecal elastase-1 concentration was the only variable independently associated with a high fecal calprotectin concentration.
CONCLUSIONS: Pancreatic insufficiency may cause intestinal inflammation, probably because of a modification of the intestinal ecology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17876545     DOI: 10.1007/s00535-007-2086-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  33 in total

1.  Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study.

Authors:  A G Røseth; M K Fagerhol; E Aadland; H Schjønsby
Journal:  Scand J Gastroenterol       Date:  1992-09       Impact factor: 2.423

2.  The ELISA fecal elastase-1 polyclonal assay reacts with different antigens than those of the monoclonal assay.

Authors:  Raffaele Pezzilli; Antonio M Morselli-Labate; Federica Palladoro; Davide Campana; Lydia Piscitelli; Paola Tomassetti; Roberto Corinaldesi
Journal:  Pancreas       Date:  2005-08       Impact factor: 3.327

3.  The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn's disease: a comparison with ultrasound.

Authors:  A Orlando; I Modesto; F Castiglione; L Scala; D Scimeca; A Rispo; S Teresi; F Mocciaro; V Criscuoli; C Marrone; P Platania; T De Falco; S Maisano; N Nicoli; M Cottone
Journal:  Eur Rev Med Pharmacol Sci       Date:  2006 Jan-Feb       Impact factor: 3.507

4.  Hydrogen breath test with glucose in exocrine pancreatic insufficiency.

Authors:  F Casellas; L Guarner; E Vaquero; M Antolín; X de Gracia; J R Malagelada
Journal:  Pancreas       Date:  1998-05       Impact factor: 3.327

5.  Concentration of pancreozymin as a determinant of the exocrine-endocrine partition of pancreatic enzymes.

Authors:  A Saito; T Kanno
Journal:  Jpn J Physiol       Date:  1973-10

6.  The pancreatitis classification of Marseilles-Rome 1988.

Authors:  H Sarles; G Adler; R Dani; C Frey; L Gullo; H Harada; E Martin; M Norohna; L A Scuro
Journal:  Scand J Gastroenterol       Date:  1989-08       Impact factor: 2.423

7.  Faecal calprotectin in children with chronic gastrointestinal symptoms.

Authors:  Alan Bremner; Sohere Roked; Rebecca Robinson; Ian Phillips; Mark Beattie
Journal:  Acta Paediatr       Date:  2005-12       Impact factor: 2.299

8.  Study of the possible enteropancreatic circulation of pancreatic amylase in the dog.

Authors:  M D Levitt; C J Ellis; S M Murphy; M L Schwartz
Journal:  Am J Physiol       Date:  1981-07

9.  Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration.

Authors:  E Bruzzese; V Raia; G Gaudiello; G Polito; V Buccigrossi; V Formicola; A Guarino
Journal:  Aliment Pharmacol Ther       Date:  2004-10-01       Impact factor: 8.171

Review 10.  Laboratory markers in IBD: useful, magic, or unnecessary toys?

Authors:  S Vermeire; G Van Assche; P Rutgeerts
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

View more
  9 in total

Review 1.  Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review.

Authors:  Bashaar Alibrahim; Mohammed I Aljasser; Baljinder Salh
Journal:  Can J Gastroenterol Hepatol       Date:  2015-04

2.  Use of a Liquid Supplement Containing 2 Human Milk Oligosaccharides: The First Double-Blind, Randomized, Controlled Trial in Pre-term Infants.

Authors:  Jean-Michel Hascoët; Marie Chevallier; Catherine Gire; Roselyne Brat; Jean-Christophe Rozé; Karine Norbert; Yipu Chen; Mickaël Hartweg; Claude Billeaud
Journal:  Front Pediatr       Date:  2022-04-25       Impact factor: 3.569

Review 3.  Chronic pancreatitis: maldigestion, intestinal ecology and intestinal inflammation.

Authors:  Raffaele Pezzilli
Journal:  World J Gastroenterol       Date:  2009-04-14       Impact factor: 5.742

4.  Evidence for a Cystic Fibrosis Enteropathy.

Authors:  Marlou P M Adriaanse; Linda J T M van der Sande; Anita M van den Neucker; Paul P C A Menheere; Edward Dompeling; Wim A Buurman; Anita C E Vreugdenhil
Journal:  PLoS One       Date:  2015-10-20       Impact factor: 3.240

5.  The effect of bariatric surgery on intestinal absorption and transit time.

Authors:  Kirstin A Carswell; Royce P Vincent; Ajay P Belgaumkar; Roy A Sherwood; Stephanie A Amiel; Ameet G Patel; Carel W le Roux
Journal:  Obes Surg       Date:  2014-05       Impact factor: 4.129

Review 6.  Pancreatic Disorders in Children with Inflammatory Bowel Disease.

Authors:  Piotr Jakimiec; Katarzyna Zdanowicz; Kamila Kwiatek-Sredzinska; Aleksandra Filimoniuk; Dariusz Lebensztejn; Urszula Daniluk
Journal:  Medicina (Kaunas)       Date:  2021-05-11       Impact factor: 2.430

7.  Markers of Bone Metabolism in Patients With Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma.

Authors:  Raffaele Pezzilli; Gian Vico Melzi d'Eril; Alessandra Barassi
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

8.  Fecal Calprotectin, Elastase, and Alpha-1-Antitrypsin Levels After Roux-en-Y Gastric Bypass; Calprotectin Is Significantly Elevated in the Majority of Patients.

Authors:  Thomas C C Boerlage; Floris Westerink; Dennis C W Poland; Inge L Huibregtse; Yair I Z Acherman; Victor E A Gerdes
Journal:  Obes Surg       Date:  2016-12       Impact factor: 4.129

Review 9.  Dietary Considerations in Autism Spectrum Disorders: The Potential Role of Protein Digestion and Microbial Putrefaction in the Gut-Brain Axis.

Authors:  Megan R Sanctuary; Jennifer N Kain; Kathleen Angkustsiri; J Bruce German
Journal:  Front Nutr       Date:  2018-05-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.